Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 02  •  04:00PM ET
52.39
Dollar change
+1.51
Percentage change
2.97
%
Index- P/E15.26 EPS (ttm)3.43 Insider Own0.00% Shs Outstand3.37B Perf Week-0.32%
Market Cap176.48B Forward P/E14.88 EPS next Y3.52 Insider Trans- Shs Float3.37B Perf Month10.46%
Enterprise Value187.28B PEG2.69 EPS next Q0.92 Inst Own9.04% Short Float0.85% Perf Quarter-10.81%
Income15.29B P/S3.78 EPS this Y15.71% Inst Trans-1.32% Short Ratio1.68 Perf Half Y-24.26%
Sales46.69B P/B8.70 EPS next Y-3.79% ROA21.83% Short Interest28.49M Perf YTD2.97%
Book/sh6.02 P/C34.41 EPS next 5Y5.53% ROE68.30% 52W High93.80 -44.15% Perf Year-38.89%
Cash/sh1.52 P/FCF17.64 EPS past 3/5Y25.78% 21.74% ROIC37.50% 52W Low43.08 21.61% Perf 3Y-21.37%
Dividend Est.1.77 (3.38%) EV/EBITDA8.13 Sales past 3/5Y23.46% 18.15% Gross Margin81.93% Volatility1.67% 2.21% Perf 5Y50.91%
Dividend TTM1.73 (3.30%) EV/Sales4.01 EPS Y/Y TTM11.24% Oper. Margin42.41% ATR (14)1.50 Perf 10Y81.63%
Dividend Ex-DateAug 18, 2025 Quick Ratio0.57 Sales Y/Y TTM18.71% Profit Margin32.76% RSI (14)60.30 Recom2.24
Dividend Gr. 3/5Y28.20% 21.81% Current Ratio0.78 EPS Q/Q-21.84% SMA205.63% Beta0.66 Target Price60.03
Payout35.93% Debt/Eq0.60 Sales Q/Q11.80% SMA506.40% Rel Volume0.67 Prev Close50.88
Employees76302 LT Debt/Eq0.52 EarningsNov 05 BMO SMA200-12.34% Avg Volume16.99M Price52.39
IPOApr 30, 1981 Option/ShortYes / Yes EPS/Sales Surpr.-9.41% -3.47% Trades Volume11,357,122 Change2.97%
Date Action Analyst Rating Change Price Target Change
Dec-08-25Downgrade Argus Buy → Hold
Oct-27-25Resumed Jefferies Underperform
Oct-01-25Upgrade HSBC Securities Hold → Buy
Sep-29-25Downgrade Morgan Stanley Equal-Weight → Underweight $47
Sep-17-25Upgrade Berenberg Hold → Buy
Sep-16-25Upgrade Rothschild & Co Redburn Neutral → Buy
Sep-09-25Upgrade Bernstein Mkt Perform → Outperform
Aug-13-25Upgrade BNP Paribas Exane Underperform → Neutral $54
Aug-05-25Downgrade UBS Buy → Neutral
Jul-31-25Downgrade HSBC Securities Buy → Hold $57
Jan-03-26 01:43PM
Jan-02-26 05:45PM
09:51AM
09:01AM
07:29AM
01:10AM Loading…
Jan-01-26 01:10AM
Dec-31-25 05:05PM
03:08PM
08:07AM
07:36AM
Dec-30-25 02:32PM
11:57AM
11:05AM
09:49AM
06:08AM
11:59PM Loading…
Dec-29-25 11:59PM
01:27PM
12:45PM
09:05AM
09:00AM
08:46AM
07:06AM
06:44AM
05:24AM
04:43AM
Dec-28-25 02:17PM
Dec-26-25 02:56PM
01:42PM
12:42PM
12:41PM
12:05PM Loading…
12:05PM
11:37AM
10:10AM
08:01AM
Dec-25-25 12:05PM
09:00AM
06:40AM
12:47AM
Dec-24-25 05:46PM
05:45PM
10:49AM
06:25AM
03:47AM
Dec-23-25 06:55PM
06:17PM
06:00PM
05:23PM
05:17PM
05:11PM
05:06PM
04:55PM
04:48PM
04:41PM
04:24PM
04:15PM
04:05PM
04:03PM
04:01PM
03:59PM
03:16PM
02:51PM
02:24PM
01:23PM
01:04PM
12:17PM
11:37AM
11:33AM
11:31AM
11:27AM
10:46AM
10:38AM
10:36AM
10:29AM
10:15AM
10:14AM
09:52AM
09:48AM
09:42AM
09:39AM
09:38AM
09:11AM
09:09AM
09:07AM
07:35AM
07:05AM
06:51AM
06:37AM
06:28AM
06:13AM
05:48AM
05:05AM
04:10AM
01:49AM
12:48AM
Dec-22-25 06:34PM
06:29PM
09:23AM
03:58AM
Dec-21-25 03:00PM
Dec-19-25 09:31PM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Nordisk A/S10% OwnerMay 30 '25Proposed Sale2.14921,8971,972,859May 30 08:31 AM